Clinical Trials Logo

Clinical Trial Summary

The main goal of this study is to test two new radioactive drugs, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in human subjects with congestive heart failure.

Evaluations of these imaging agents will include their uptake in heart, lungs and liver, their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies, the better of the two drugs will be chosen for further studies in patients with heart disease. After the better compound is chosen, additional measures of its imaging properties, metabolism and pharmacokinetics will be done in subjects with heart failure.


Clinical Trial Description

The human heart contains many nerve fibers that are involved in controlling the heart's pumping function. Several heart diseases have been shown to damage the nerves in the heart. Studies have shown that damage to the heart nerves may be a cause of death in patients with diseases like heart failure or diabetes.

Two new radioactive drugs been developed at the University of Michigan for taking pictures of the nerve fibers in the heart using a medical imaging method called positron emission tomography (PET).

These two drugs are 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG). Initial PET imaging studies in normal human subjects (see NCT 02385877) have shown that [18F]4F-MHPG and [18F]3F-PHPG are each able to provide a detailed regional map of the distribution of nerve fibers in the heart.

In Stage 1 of this study, enrolled subjects with heart failure will undergo PET studies with [18F]4F-MHPG and [18F]3F-PHPG to allow direct comparison of the imaging properties, metabolism and pharmacokinetics of the two radioactive drugs in the same subjects.

A third PET scan with [13N]ammonia will be done to assess resting blood flow in different areas of the heart. The results of these studies will be used to select the better of the two tracers for further study in patients with heart disease.

In Stage 2 of the study, enrolled subjects with heart failure will undergo additional PET evaluations of the imaging properties and kinetics of the cardiac nerve tracer selected in Stage 1 (either [18F]4F-MHPG or [18F]3F-PHPG).

Again, a PET scan with [13N]ammonia will also be performed to measure regional resting blood flow. A third PET scan with [11C]meta-hydroxyephedrine ([11C]HED), an established cardiac nerve tracer, will also be done to address research questions related to the mechanisms involved in the retention of [18F]4F-MHPG and [18F]3F-PHPG inside the nerve of the heart.

For all study stages, subjects will be assessed during the scan for heart rate, blood pressure and oxygen saturation. Patients will be followed at 30 min, 24 hours and 30 hours regarding any adverse events or serious adverse events they might have experienced. These will be reported as required. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02669563
Study type Interventional
Source University of Michigan
Contact
Status Completed
Phase Early Phase 1
Start date December 2015
Completion date December 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2
Completed NCT02892448 - Cardiac MRI for Metal on Metal Hip Resurfacing N/A
Active, not recruiting NCT02537782 - Myocardial Work and Metabolism in CRT N/A
Completed NCT02525185 - Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy
Terminated NCT01705509 - The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC) N/A
Completed NCT00999947 - Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy N/A
Completed NCT00626028 - Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing Phase 3
Recruiting NCT00138931 - Genetics of Cardiovascular and Neuromuscular Disease
Withdrawn NCT02838355 - Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients N/A
Completed NCT01085955 - Investigation in Pregnancy Associate Cardiomyopathy N/A
Withdrawn NCT00428103 - Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy N/A
Recruiting NCT00273637 - Registry and Survey of Women With Pregnancy Related Cardiomyopathy N/A
Completed NCT00810550 - Carotid Ultrasound in the Evaluation of Heart Failure N/A
Completed NCT04603521 - Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
Enrolling by invitation NCT03057561 - Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance N/A
Completed NCT00027170 - Technical Development of Cardiovascular Magnetic Resonance Imaging
Not yet recruiting NCT02917395 - Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients N/A
Completed NCT02270840 - Budapest Upgrade CRT Study (Version 009-4.1) N/A
Completed NCT02331264 - Cardiac Assessment of Patients With Hip Implants N/A
Completed NCT02164721 - Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy N/A